StockData
Ascentage Pharma Group International logo

Ascentage Pharma Group International (AAPG) company profile

AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 3/30
$13.01−0.13 (-0.97%)

Close on Nov 18, 2026Market cap $1.21BP/E –Yield –

About Ascentage Pharma Group International

Pharmaceutical Preparations, SIC 2834

Ascentage Pharma Group International is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and pharmaceutical products. The company develops clinical and preclinical drug candidates, with primary commercial products including Olverembatinib and Lisaftoclax. Its operations center on pharmaceutical product sales, commercialization rights agreements, intellectual property licensing, and management services. The company provides its pharmaceutical products to patients needing medical treatment, while also collaborating with and serving biopharmaceutical industry partners such as Innovent and Takeda.

The enterprise maintains substantive business operations in China and the United States, alongside clinical research activities that receive government tax credits and subsidies in Australia. It has manufacturing facilities and conducts operations through multiple subsidiaries. The company is incorporated in the Cayman Islands, with its principal executive offices located in Suzhou, China, and an additional corporate office located in Rockville, Maryland.

Summary of the business section of Ascentage Pharma Group International's latest annual report, written by StockData.

Company profile

Company

Legal name
Ascentage Pharma Group International
Founded
2009
Headquarters
Suzhou , Jiangsu, China
Address
68 Xinqing Road, Suzhou Industrial Park
Phone
86 512 8555 7777
Employees
767, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Ernst & Young Hua Ming LLP, China

Stock & identifiers

Ticker
AAPG
Exchange
Nasdaq
IPO date
Jan 24, 2025
Shares outstanding
373M, Apr 1, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
2023311
CUSIP
04390B105
ISIN
US04390B1052
FIGI
BBG01RJXM9C9
Share class FIGI
BBG01RJXMB89
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Dajun YangChairman and CEO, Director37,742,091
Faical MiyaraChief Business Officer–
Yifan ZhaiChief Medical Officer37,742,091
Veet MisraChief Financial Officer–
Jin CaoChief Accounting Officer5,400
Thomas J. KnappSVP/General Counsel362,444
Shaomeng WangDirector10,053,943
Ren WeiDirector8,964
Marc E. LippmanDirector21,174
David SidranskyDirector10,641
Marina BozilenkoDirector–
Debra YuDirector–
Simon Dazhong LuDirector41,457
Changqing YeDirector8,964

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 24, 2025
Offer price
$17.25
Securities offered
7,325,000
Gross proceeds
$126.36M
Exchange
Nasdaq
First trading day
Jan 24, 2025
First-day close
$17.38+0.8%
Lock-up ends (est.)
Jul 23, 2025

“The initial public offering price of the ADSs is US$17.25 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 767 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?